Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

COVID-19 Antibody Responses In Cystic Fibrosis: CAR-CF

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05054582
Recruitment Status : Recruiting
First Posted : September 23, 2021
Last Update Posted : September 28, 2021
Sponsor:
Collaborators:
Queen's University, Belfast
European Cystic Fibrosis Society - Clinical Trial Network
Cystic Fibrosis Foundation
Information provided by (Responsible Party):
Medical University Innsbruck

Brief Summary:

Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in people with CF (pwCF) is due to enhanced infection prevention practices or whether pwCF have protective genetic/immune factors. This study aims to prospectively assess the proportion of pwCF, including both adults and children with CF who have evidence of SARS-CoV-2 antibodies over a two-year period. This study will also examine whether pwCF who have antibodies for SARS-CoV-2 have a different clinical presentation and what impact this has on their CF disease. The proposed study will recruit pwCF from paediatric and adult CF centres throughout the United Kingdom. Serological testing to detect antibodies will be performed on blood samples taken at month 0, 6, 12, 18 and 24 with additional time-points if bloodwork is available via normal clinical care. Clinical data on, lung function, CF-related medical history, pulmonary exacerbations, antibiotic use, and microbiology and vaccination receipt, will be collected during routine clinical assessments.

Associations will be examined between socio-demographic and clinical variables and serologic testing. The effects of SARS-CoV-2 infection on clinical outcomes and analyse end-points will be examined to explore any age-related or gender-based differences, as well as subgroup analysis of outcomes in lung-transplant recipients and pwCF receiving CFTR modulator therapies. As pwCF receive COVID-19 vaccination a comparison of the development and progression of anti-SARS-CoV-2 antibodies in pwCF following natural infection and vaccination SARS-CoV-2 over time will be performed.


Condition or disease
Cystic Fibrosis Covid19

Detailed Description:

This is a prospective, longitudinal cohort study in people with Cystic Fibrosis (pwCF) that involves repeated serial sampling of participants. This study design was chosen to provide comprehensive information on SARS-CoV-2 seroprevalence changes over time and the subsequent clinical impact on pwCF. The study will be conducted at participating CF centres over a 3-year period. Study participants will include paediatric and adult pwCF. For the UK section of the study, UK investigators in the European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) will be invited to participate. Participating investigators can enrol all eligible pwCF over a 12-month period. Participants are then followed up for 24 months. Participants will donate blood samples at their routine clinic visits. Blood samples will be collected at Day 0 (baseline), at Months 6, 12, 18 and 24 (to coincide with routine clinical reviews). Additional blood samples will be taken opportunistically every time the participant visits the clinic for blood draws. These blood samples could be related to, routine care, annual review visits, pulmonary exacerbations (PEx), CF complications or when initiating new treatments (e.g. CFTR modulators).

Serum from blood samples will be shipped to a central laboratory (Queen's University Belfast) for standardized measurement of SARS-CoV-2 antibodies.

Alongside the blood samples the investigators will also collect clinical data from the patient's health records and will input this data into the case report form (CRF). Clinical data will be collected in conjunction with routine care visits, according to local clinical practice. Investigators will collect data elements from information routinely recorded in the patients' medical records. Data will be collected at baseline, month 6, 12, 18 and 24 as per the study schedule, and at additional blood sampling timepoints as previously explained above. Data collection will include routine data

available from CF clinic follow-ups including background demographic information, CF medical history, medications, exacerbation information, sputum microbiology and clinical and lung function parameters. Information on SARS-CoV-2 infection history and vaccine receipt will also be collected.

The maximum follow-up duration of participation in the study for each patient will be 24 months. This study duration (24-month follow-up) is justified as it provides sufficient time to observe changes in antibody prevalence over the course of the COVID-19 pandemic as well as sufficient time to determine long term clinical outcomes for pwCF who are SARS-CoV-2 seropositive. Furthermore, we anticipate the 2-year study follow-up period will provide sufficient time to observe the impact of vaccination on antibody levels given that a number of vaccines are now commercially available.

The investigators will compare the level of antibody responses between natural COVID-19 infection and vaccination in pwCF and how this varies over time. This will be achieved by analyzing seroprevalence and antibody levels according to natural infection and vaccination status and according to time of sample post infection or post vaccination, if known.

Optional Study sample collection:

For participants who consent, a second blood sample will also be drawn into EDTA tubes (plasma). Consent to this optional study sample would allow this sample and any remaining serum (following antibody testing) to be stored for future analysis and allow further research to be carried out on related studies to COVID-19 and CF.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 150 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: COVID-19 Antibody Responses In Cystic Fibrosis: CAR-CF
Actual Study Start Date : September 1, 2021
Estimated Primary Completion Date : September 30, 2024
Estimated Study Completion Date : September 30, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis




Primary Outcome Measures :
  1. SARS-COV-2 seroprevalence [ Time Frame: 3-year period (comprising a 1-year enrollment period and a 2-year follow-up) ]
    proportion of pwCF with at least 1 seropositive result over the study period and the difference in this proportion by age, geographical area and over time.

  2. Association of SARS-CoV-2 seropositivity, clinical symptoms and clinical outcomes in pwCF [ Time Frame: 3-year period (comprising a 1-year enrollment period and a 2-year follow-up) ]
    incidence of symptomatic COVID-19 over the study period and severity; proportion of seropositive pwCF with subsequent CF exacerbation compared to pwCF who are seronegative; death rate in pwCF with at least one seropositive result compared to pwCF who are seronegative.

  3. Longitudinal comparison of the detection including level and duration of anti-SARS-CoV-2 antibodies in pwCF following natural infection and SARS-CoV-2 vaccination. [ Time Frame: 3-year period (comprising a 1-year enrollment period and a 2-year follow-up) ]
    Longitudinal comparison of the detection including level and duration of anti-SARS-CoV-2 antibodies in pwCF following natural infection and SARS-CoV-2 vaccination.


Secondary Outcome Measures :
  1. Serum proteomic and genomic responses of pwCF who are SARS-CoV-2 seropositive an seronegative. [ Time Frame: anticipated 5-10 years ]
    Serum proteomic and genomic responses of pwCF who are SARS-CoV-2 seropositive an seronegative.


Biospecimen Retention:   Samples With DNA
Samples With DNA Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Consenting people with cystic fibrosis of any age, genotype, transplant status and disease severity will be eligible to participate in the study. The study population is expected to be representative of the general CF population.
Criteria

Inclusion Criteria:

  • Consenting people with cystic fibrosis of any age, genotype, transplant status and disease severity

Exclusion Criteria:

  • Refusal to give informed consent
  • Contraindication to venepuncture

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05054582


Contacts
Layout table for location contacts
Contact: Helmut f Ellemunter, MD +4350504 ext 23592 helmut.ellemunter@i-med.ac.at
Contact: Nikelwa Theileis, M.A. +4350504 ext 23592 nikelwa.theileis@i-med.ac.at

Locations
Layout table for location information
Austria
CF Centre Innsbruck, Medical University of Innsbruck, Univ. Clinic for Paediatics III Recruiting
Innsbruck, Tirol, Austria, 6020
Contact: Helmut Ellemunter, MD    +4350504 ext 23592    helmut.ellemunter@i-med.ac.at   
Contact: Nikelwa Theileis, M.A.    +4350504 ext 23592    nikelwa.theileis@i-med.ac.at   
Sub-Investigator: Johannes Eder, MD         
Sub-Investigator: Dorothea Appelt, Dr. med.         
Sub-Investigator: Teresa Fuchs, Dr. med.         
Sponsors and Collaborators
Medical University Innsbruck
Queen's University, Belfast
European Cystic Fibrosis Society - Clinical Trial Network
Cystic Fibrosis Foundation
Investigators
Layout table for investigator information
Principal Investigator: Helmut Ellemunter, MD Medical University of Innsbruck, CF Centre Innsbruck, Univ. Clinic for Paediatrics III
Layout table for additonal information
Responsible Party: Medical University Innsbruck
ClinicalTrials.gov Identifier: NCT05054582    
Other Study ID Numbers: CAR-CF V1.0_21April2021
First Posted: September 23, 2021    Key Record Dates
Last Update Posted: September 28, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Medical University Innsbruck:
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Cystic Fibrosis
Fibrosis
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases